<DOC>
	<DOCNO>NCT00006212</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Drugs phosphorus-32 may make tumor cell sensitive radiation therapy . Chemotherapy combine radiation therapy phosphorus-32 may kill tumor cell . PURPOSE : Phase I trial study effectiveness phosphorus-32 plus radiation therapy chemotherapy treat patient stage II stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Phosphorus-32 Plus Radiation Therapy Chemotherapy Treating Patients With Stage II Stage III Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine dosimetry toxicity interstitial phosphorus P32 colloid plus chemotherapy radiotherapy patient previously untreated stage II , IIIA , IIIB non-small cell lung cancer . II . Determine maximum tolerate dose phosphorus P32 colloid patient . III . Determine response patient treat regimen . OUTLINE : This dose escalation study phosphorus P32 colloid . Patients receive vinblastine IV day 1 , 8 , 15 , 22 , 29 ; cisplatin IV 30-60 minute day 1 29 ; phosphorus P32 colloid interstitially day 50 . Patients tumor size le 8.0 cm receive radiotherapy follow phosphorus P32 injection 5 day week 6.5 week . Patients tumor size great 8.0 cm receive radiotherapy 5 day week 4.5 week prior phosphorus P32 injection , additional 2.5 week follow injection . Cohorts 3 patient receive escalate dos phosphorus P32 colloid maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 patient experience dose limit toxicity . Patients follow every 3 month 2 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm , previously untreated stage II , IIIA , IIIB nonsmall cell lung cancer Unresectable inoperable disease OR Refusal surgery Tumor reachable CT guide needle placement Bidimensionally measurable disease chest xray CT scan No clinical/radiographic evidence metastatic disease PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Neutrophil count least 1,900/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9 g/dL ( transfusion allow ) Hepatic : Adequate hepatic function Renal : BUN great 25 mg/dL Creatinine great 1.5 mg/dL Other : Less 5 % weight loss Able receive induction chemotherapy No second malignancy within past 5 year except skin cancer Not pregnant Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy thorax Surgery : See Disease Characteristics No prior resection primary site</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2001</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>